Luteolin alters MUC1 extracellular domain, sT antigen, ADAM‑17, IL‑8, IL‑10 and NF‑κB expression in Helicobacter pylori‑infected gastric cancer CRL‑1739 cells: A preliminary study
- Iwona Radziejewska
- Małgorzata Borzym‑Κluczyk
- Katarzyna Leszczyńska
Affiliations: Department of Medical Chemistry, Medical University of Białystok, Białystok, 15‑222 Podlaskie Voivodeship, Poland, Department of Pharmaceutical Biochemistry, Medical University of Białystok, Białystok, 15‑222 Podlaskie Voivodeship, Poland, Department of Microbiology, Medical University of Białystok, Białystok, 15‑222 Podlaskie Voivodeship, Poland
- Published online on: November 25, 2020 https://doi.org/10.3892/br.2020.1395
Copyright: © Radziejewska
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Luteolin is a natural flavonoid possessing certain beneficial pharmacological properties, including anti‑oxidant, anti‑inflammatory, anti‑microbial and anti‑cancer properties. The majority of types of gastric cancer with chronic gastritis are caused by infection with Helicobacter pylori (H. pylori). The present study evaluated the effect of luteolin on a number of selected factors that are potentially involved in gastric cancer development. The study was performed using gastric cancer CRL‑1739 cells treated with 30 µM luteolin and H. pylori alone or combined. ELISA and reverse transcription PCR were used to assess the expression levels of MUC1, GalNAcα‑R (Tn antigen) and NeuAcα2‑3Galβ1‑3GalNAc‑R (sT antigen), ADAM‑17, IL‑8, IL‑10 and NF‑κB. H. pylori and luteolin independently and in combination significantly reduced the expression levels of the extracellular domain of MUC1 in gastric cancer cells compared with the untreated control cells. ADAM‑17 expression was reduced by treatment with the pathogen and luteolin. Additionally, both factors reduced sT antigen expression. Treatment with 30 ≤M luteolin significantly induced IL‑8 expression at the mRNA and protein level, and the mRNA expression levels of IL‑10 and NF‑κB compared with the control. Both H. pylori and luteolin induced IL‑8 protein expression. The present preliminary results suggest that luteolin may be used to treat patients with gastric cancer.